Survival of Heparins, Oral Anticoagulants, and Aspirin after the Year 2010

Jawed Fareed, Ph.D., D.Sc.,1 Debra A. Hoppensteadt, Ph.D.,1 Daniel Fareed,2 Muzaffer Demir, M.D.,3 Rakesh Wahi, M.D.,4 Melaine Clarke,2 Cafer Adiguzel, M.D.,1 and Rodger Bick, M.D., Ph.D., F.A.C.P.5

In reference to the above-mentioned article in Seminars in Thrombosis and Hemostasis, Volume 34, Number 1, pages 58–73, a nonreferenced statement regarding the closure of a large clinical trial with prasugrel due to bleeding was made due to an inadvertent misinterpretation. Upon review of the published data on the clinical trials on prasugrel and the ongoing trials, the authors did not find any information on the closure of either a large or small trial on this drug. The authors acknowledge the readjustment of the recruitment schedule of two smaller trials, which were temporarily suspended last year, and that have since either completed enrollment or are still enrolling participants. The authors regretfully acknowledge the statement made in the aforementioned article, reaffirm that to their knowledge that no large clinical trials with prasugrel have been closed due to bleeding, and will accordingly update this information in their records and future publications.

1Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, Illinois; 2Pathology Department, Loyola University Medical Center, Chicago, Illinois; 3Trakya University School of Medicine, Department of Medicine, Division of Hematology, Edirne, Turkey; 4Grant Memorial Hospital, Petersburg, West Virginia; 5University of Texas Southwestern Medical Center, Dallas, Texas.
